Navigation Links
GenVec Reports Third Quarter 2009 Financial Results
Date:11/5/2009

e replay, go to www.genvec.com, click on "Investor Relations," and click on "Webcasts and Data."

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, influenza, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to certain of our product candidates being in early stages of development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of thi
'/>"/>

SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. GenVec Announces Third Quarter 2009 Results Conference Call
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...wswire-FirstCall/--deCODE,genetics,Inc.(Nasdaq: DC...asdaqStockMarketthattradinginthecompany,scommonsto...Ewillbefiledwiththe,SecuritiesandExchangeCommissio...Nasdaq,unlessthecompanyfilesanappealtotheNasdaq,Li...ppeal,which,willstaythesuspensionanddelistingthrou...
(Date:11/24/2009)...wswire-FirstCall/--deCODE,genetics,Inc.(Nasdaq: DC...motionsbytheU.S.BankruptcyCourtfortheDistrictofDel...oluntarypetitionfor,reliefunderChapter11oftheUnite..., TheordersissuedbytheBankruptcyCourtallowthecomp...11proceedings.Inparticular,the,companyreceivedinte...
(Date:11/24/2009)...-ShanghaiBiolaxyannouncedthe,ChineseStateFood&...onalnewdrugapplication(IND)foritsoralinsulinprojec...abetes.ThisIND,approvalallowsBiolaxytoinitiateitsf...rcharacteristicofhighbloodglucoseandpoor,metabolis...ro-and,macro-vasculardiseases,lossofvision,kidneyf...
(Date:11/24/2009)...forpatientswithadvanced-stage,orrecurrentendometri...tCall/-AEternaZentarisInc.(NASDAQ: AEZS ;TSX:AEZ)(...edonendocrinetherapyandoncology,todayannouncedposi...otoxicpeptideconjugate,AEZS-108(formerlyAN-152),in...napersonalizedhealthcareapproach,thestudyselectedp...
Breaking Biology Technology:deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics"...ata from three clinical trials using REOLYSIN are ...iety of Clinical Oncology (ASCO) Annual Meeting. T... 29-June 2, 2009. The abstracts are available on t... REOLYSIN poster presentations, - Dr. Monica ...
...Calif., May 14 Bayer HealthCare Pharmaceuticals, ...X ) today announced that more than 65 studies eval...ill be presented at the 2009 American Society of C...var has a proven track record in two cancers - in ...noma (HCC), or liver cancer, and in the treatment ...
...T NOW(R), the first retail direct-access lab testi...s partnered with Atherotech, Inc., a Birmingham, A... Cholesterol Test direct to consumers at an afford...d cholesterol profile that identifies a greater nu...l test to directly measure LDL. , , ANY LAB TEST...
Other Biology Technology:Oncolytics Biotech(R) Inc.'s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference 2Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 2Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 3Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 4Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 5Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 6VAP(R) Cholesterol Test Now Available at ANY LAB TEST NOW(R) 2VAP(R) Cholesterol Test Now Available at ANY LAB TEST NOW(R) 3
(Date:11/25/2009)...sy lives. In addition to mammalian immune systems ...alled bacteriophages, viruses that kill half the b...ria and another class of microorganisms called arc...h as deep-sea volcanic vents) manage just fine, th...nse system that helps protect them from many virus...
(Date:11/25/2009)... professors recently received funding from the Nat...h beneficial to understanding the environment. The...kwood, assistant professor in the Department of Bi...wo separate research projects. , His first proje...es and Functions from the Leaf to the Landscape," ...
(Date:11/24/2009)...ein that may help gut bacteria bind to the gastroi...iotic producers to identify strains that are likel...need to interact with cells lining the gut to have...es in the gut they are more likely to stick around...halie Juge from the Institute of Food Research. I...
Breaking Biology News(10 mins):Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3Kent State University professors focus research on the environment with grants totaling $890,000 2A sticky solution for identifying effective probiotics 2When palm trees gave way to spruce trees 8890 1When palm trees gave way to spruce trees 8890 2St Gallen consensus 2009 3A A radically different approach to treating early breast cancer 49311 1St Gallen consensus 2009 3A A radically different approach to treating early breast cancer 49311 2St Gallen consensus 2009 3A A radically different approach to treating early breast cancer 49311 3National Changing Diabetes Program Issues Statement on President Obamas Speech to the American Medical Association 49308 1
...sions with a sticky protein on the tip that lets t...e structure of the protrusions helps the bacteria ...e the body, researchers report in the journal PLoS...ity of Washington in Seattle and ETH Zurich in Swi...oli attaches to mucous membranes in the body. In t...
...age to exist and even thrive in surroundings rangi...of scientists from the Weizmann Institute,s Plant ...has found that a switch in just two amino acids (t...ce between functioning best at moderate temperatur...e results of their research, which recently appear...
...ect Antarctica ?the world,s last great wilderness ... at a meeting of Antarctic experts in Edinburgh. ,...aty Consultative Meeting, which finished at Edinbu...une, agreed new measures that will reduce the risk...marine and terrestrial ecosystems in Antarctica. ,...
Other Biology News:Tiny shock absorbers help bacteria stick around inside the body 2Bacteria beat the heat 2Antarctic Treaty Meeting moves to protect frozen continent from non-native species 2
Pig Trypsin from BIOPUR
Rabbit Anti-Human PALLD Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Cloning and Expression Services from Molecular Biology Resources
Cat IgA ELISA Kit from Bethyl Laboratories
Biology Products: